search
Back to results

Methacholine, Long-acting M-cholinolytic and beta2-agonist on the Activity of Beta-receptors in Healthy Volunteers

Primary Purpose

Health, Subjective, Hyperreactivity, Bronchial

Status
Unknown status
Phase
Not Applicable
Locations
Russian Federation
Study Type
Interventional
Intervention
Formoterol
Tiotropium Bromide
metacholine test
Sponsored by
Federal State Budgetary Institution, Pulmonology Scientific Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Health, Subjective focused on measuring beta-receptors, metacholine, formoterol, tiotropium

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

1 Provision of signed and dated informed consent form 2. Healthy male or female, aged 18-60 years

Exclusion Criteria:

  • Participants unable to perform spirometry
  • Exacerbation respiratory infection within the previous four weeks
  • Hypersensitivity or allergy to formoterol, metacholine or tiotropium bromide
  • Females who are currently pregnant and lactating
  • major surgery in the last 6 months
  • Refusal to participate
  • Currently participating in another clinical study

Sites / Locations

  • Kirill ZykovRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

smoking

non-smoking

Arm Description

Healthy smoking volunteers

Healthy non-smoking volunteers

Outcomes

Primary Outcome Measures

Change from baseline beta-receptor binding activity at 60 min after the inhalation of formoterol or tiotropium.
Beta-receptor binding activity will be measured with modified radioligand method before and after 60 min after the inhalation of formoterol or tiotropium
Change from baseline beta-receptor binding activity at 40 min after the challenge test with metacholine.
Beta-receptor binding activity will be measured with modified radioligand method before and after 40 min after the challenge test with metacholine.

Secondary Outcome Measures

Comparison of beta-receptor binding activity measured with modified radioligand after formoterol and tiotropium.
Difference of change of beta-receptor binding activity measured with modified radioligand method before and after 60 min after the inhalation of formoterol and tiotropium.
Comparison of beta-receptor binding activity measured with modified radioligand method after formoterol or tiotropium in smokers and non-smokers.
Difference of change of beta-receptor binding activity measured with modified radioligand method before and after 60 min after the inhalation of formoterol or tiotropium in smokers and non-smokers.
Comparison of beta-receptor binding activity measured with modified radioligand after metacholine
Difference of change of beta-receptor binding activity measured with modified radioligand method before and after inhalation of metacholine
Comparison of beta-receptor binding activity measured with modified radioligand method after inhalation of metacholine in smokers and non-smokers.
Difference of change of beta-receptor binding activity measured with modified radioligand method before and after inhalation of metacholine

Full Information

First Posted
October 11, 2019
Last Updated
October 22, 2019
Sponsor
Federal State Budgetary Institution, Pulmonology Scientific Research Institute
Collaborators
Moscow State University of Medicine and Dentistry, National Medical Research Center for Cardiology, Ministry of Health of Russian Federation, Branch of Shemyakin-Ovchinnikov Institute of Bioorganic chemistry of RAS
search

1. Study Identification

Unique Protocol Identification Number
NCT04137029
Brief Title
Methacholine, Long-acting M-cholinolytic and beta2-agonist on the Activity of Beta-receptors in Healthy Volunteers
Official Title
Effect of Methacholine, Long-acting M-cholinolytic and beta2-agonist on the Binding Activity of Beta-receptors in Healthy Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Unknown status
Study Start Date
April 24, 2019 (Actual)
Primary Completion Date
July 2020 (Anticipated)
Study Completion Date
October 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Federal State Budgetary Institution, Pulmonology Scientific Research Institute
Collaborators
Moscow State University of Medicine and Dentistry, National Medical Research Center for Cardiology, Ministry of Health of Russian Federation, Branch of Shemyakin-Ovchinnikov Institute of Bioorganic chemistry of RAS

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Interventional open-labeled study in parallel groups is aimed to evaluate changes of beta receptors in healthy volunteers under the influence of inhaled metacholine, long-acting anticholinergics and beta-agonists using modified radioligand method.
Detailed Description
Long-acting beta2-agonists and anticholinergics are main drugs in therapy of chronic obstructive pulmonary disease . Beta-agonists exert their bronchodilatory effects via β2 adrenoceptors located on airway smooth muscle cells. Anticholinergics block mainly M3-cholinoreceptors located in the airways, thus inhibiting bronchoconstriction. Metacholine blocks M2-cholinoreceptors thus inducing bronchoconstriction. It is known, that muscarine and beta-receptors interact with each other, but the detailed mechanism is unknown. For evaluating the binding activity of beta-receptors after inhalation of these drugs the modified radioligand method was used.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Health, Subjective, Hyperreactivity, Bronchial
Keywords
beta-receptors, metacholine, formoterol, tiotropium

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
There are two groups: the first group is smokers, the second group is non - smokers. The participants of both groups will receive metacholine on the first visit, formoterol 12 micrograms on the second visit, then tiotropium bromide 18 mkg on the third visit.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
smoking
Arm Type
Experimental
Arm Description
Healthy smoking volunteers
Arm Title
non-smoking
Arm Type
Experimental
Arm Description
Healthy non-smoking volunteers
Intervention Type
Drug
Intervention Name(s)
Formoterol
Intervention Description
The participants will receive inhalation of formoterol 12 micrograms
Intervention Type
Drug
Intervention Name(s)
Tiotropium Bromide
Intervention Description
The participants will receive inhalation of tiotropium bromide 18 mkg once
Intervention Type
Diagnostic Test
Intervention Name(s)
metacholine test
Intervention Description
The participants will receive inhalation of metacholine once
Primary Outcome Measure Information:
Title
Change from baseline beta-receptor binding activity at 60 min after the inhalation of formoterol or tiotropium.
Description
Beta-receptor binding activity will be measured with modified radioligand method before and after 60 min after the inhalation of formoterol or tiotropium
Time Frame
Baseline (pre-dose), 60 minutes
Title
Change from baseline beta-receptor binding activity at 40 min after the challenge test with metacholine.
Description
Beta-receptor binding activity will be measured with modified radioligand method before and after 40 min after the challenge test with metacholine.
Time Frame
Baseline (pre-dose), 40 minutes
Secondary Outcome Measure Information:
Title
Comparison of beta-receptor binding activity measured with modified radioligand after formoterol and tiotropium.
Description
Difference of change of beta-receptor binding activity measured with modified radioligand method before and after 60 min after the inhalation of formoterol and tiotropium.
Time Frame
Baseline (pre-dose), 60 minutes
Title
Comparison of beta-receptor binding activity measured with modified radioligand method after formoterol or tiotropium in smokers and non-smokers.
Description
Difference of change of beta-receptor binding activity measured with modified radioligand method before and after 60 min after the inhalation of formoterol or tiotropium in smokers and non-smokers.
Time Frame
Baseline (pre-dose), 60 minutes
Title
Comparison of beta-receptor binding activity measured with modified radioligand after metacholine
Description
Difference of change of beta-receptor binding activity measured with modified radioligand method before and after inhalation of metacholine
Time Frame
Baseline (pre-dose), 40 minutes
Title
Comparison of beta-receptor binding activity measured with modified radioligand method after inhalation of metacholine in smokers and non-smokers.
Description
Difference of change of beta-receptor binding activity measured with modified radioligand method before and after inhalation of metacholine
Time Frame
Baseline (pre-dose), 40 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 1 Provision of signed and dated informed consent form 2. Healthy male or female, aged 18-60 years Exclusion Criteria: Participants unable to perform spirometry Exacerbation respiratory infection within the previous four weeks Hypersensitivity or allergy to formoterol, metacholine or tiotropium bromide Females who are currently pregnant and lactating major surgery in the last 6 months Refusal to participate Currently participating in another clinical study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kirill A Zykov, Prof
Phone
+79257729462
Email
kirillaz@inbox.ru
First Name & Middle Initial & Last Name or Official Title & Degree
Anna V Eremenko
Phone
+79265598031
Email
a_nn87@list.ru
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kirill A Zykov, Prof
Organizational Affiliation
Federal State Budgetary Institution, Pulmonology Scientific Research Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kirill Zykov
City
Moscow
ZIP/Postal Code
115682
Country
Russian Federation
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kirill Zykov, Prof
Phone
+74953956393
Email
pulmo_fmba@mail.ru
First Name & Middle Initial & Last Name & Degree
Anna Eremenko
Phone
+79265598031
Email
a_nn87@list.ru
First Name & Middle Initial & Last Name & Degree
Ann Eremenko

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
26762097
Citation
Agapova OY, Skoblov YS, Zykov KA, Rvacheva AV, Beilina VB, Masenko VP, Chazova IE. [Radioligand Method of Assessment of beta-Adrenoceptor's Activity on Human T-Lymphocytes]. Bioorg Khim. 2015 Sep-Oct;41(5):592-8. doi: 10.1134/s1068162015050027. Russian.
Results Reference
result
PubMed Identifier
28064316
Citation
Agapova OY, Skoblov YS, Tkachev GA, Mironova NA, Golitsyn SP, Masenko VP, Chazova IE, Zykov KA. [Changes in the receptor activity of beta2-adrenoreceptors of human T-lymphocytes under the effect of beta2-agonists]. Mol Biol (Mosk). 2016 Nov-Dec;50(6):999-1006. doi: 10.7868/S0026898416050025. Russian.
Results Reference
result
Citation
Smolyakova E.V., Skoblov Y.S., Skoblova N.A., Agapova O.Y., Ambat'ello L.G., Klimova A.A., Kuznetsova T.V., Masenko V.P., Nistor S.Yu., Rvacheva A.V., Chazova I.E., Zykov K.A. Specificity and Selectivity of the Modified Radioligand Method for Assessment of β1-Adrenoreceptor's Binding Activity on Human T-Lymphocytes. Russian Journal of Bioorganic Chemistry 45(3): 295-301, 2019
Results Reference
result

Learn more about this trial

Methacholine, Long-acting M-cholinolytic and beta2-agonist on the Activity of Beta-receptors in Healthy Volunteers

We'll reach out to this number within 24 hrs